I'm LongbridgeAI, I can summarize articles.cbdMD reported FY26 Q3 net sales of $5.6 million, a 20% year-over-year increase driven by wholesale growth. However, the operating loss widened to $1.13 million, with a net loss of $1.2 million per share. Gross margin declined 6.8 percentage points to 54.7% due to product mix shifts and regulatory costs. Management implemented cost cuts in July to achieve monthly savings of $100,000-$150,000.
- cbdMD posted fiscal Q3 net sales of $5.6 million, up 20% year over year, driven by a 61% wholesale jump. * Operating loss widened to $1.13 million; net loss attributable to common shareholders was $1.2 million, or $0.11 per share. * Gross margin fell 6.8 percentage points to 54.7% on mix shift to wholesale, added warehousing/repacking, higher inventory reserves tied to regulatory changes. * Oasis distributor depletions rose 25% in the quarter; Bluebird Botanicals added more than $0.5 million in its first full-quarter contribution. * Management cited July cost cuts targeting $100,000-$150,000 in monthly savings, alongside one-time M&A diligence and legal costs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. cbdMD Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL25528) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)